November 2016
Supplement
HBS Case Collection

Alnylam Pharmaceuticals: Building Value from the IP Estate (B)

By: Vicki Sato, Willy Shih and Matt Higgins

Format:Print
| Language:English
| Pages:13

Abstract

The leader of a pioneering biotech company in the siRNA space weighs his options for scaling production capacity in advance of an anticipated commercial launch. Operational complexity and relative merits of in-house manufacturing versus a contractor model are discussed.

Keywords

Pharmaceutical Companies; Pharmaceutical Industry; Biotech; Biotechnology; Operational Complexity; Strategy; Manufacturing; Production; Strategic Planning; Intellectual Property; Biotechnology Industry; United States

Citation

Sato, Vicki, Willy Shih, and Matt Higgins. "Alnylam Pharmaceuticals: Building Value from the IP Estate (B)." Harvard Business School Supplement 617-022, November 2016.